Yes, Invitae offers an out-of-pocket estimate for patients with a primary indication of hereditary breast and ovarian cancer (HBOC) or Lynch syndrome.
Although the great majority of patients who select in-network insurance billing already pay less than $100 out of pocket, the estimator brings peace of mind.
To obtain an out-of-pocket estimate during the ordering process, place your order using Invitae’s online portal and include the following information:
- Primary indication of HBOC or Lynch syndrome
- Patient name
- Patient DOB
- Insurance company
- Subscriber ID
An estimate will appear at the bottom of the “Billing information” section. The estimate will vary based on your patient’s health plan criteria and design, deductible, co-insurance, and out-of-pocket limits. The actual amount may be higher or lower due to the patient’s deductible. Please also note that the number presented is an estimate and not a prior authorization.
The estimate is also applicable to panels containing HBOC (BRCA1 and BRCA2) and/or Lynch (EPCAM, PMS2, MSH2, MLH1, and MSH6) genes, even if the primary indication is not hereditary breast and ovarian cancer (HBOC) or Lynch syndrome. In these cases, view the out-of-pocket cost estimator on the patient site.